Dublin, Dec. 15, 2016 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies" to their offering.
The delivery of drugs to central nervous system (CNS) is a challenge in the treatment of neurological disorders. Drugs may be administered directly into the CNS or administered systematically (e.g., by intravenous injection) for targeted action in the CNS. The major challenge to CNS drug delivery is the blood-brain barrier (BBB), which limits the access of drugs to the brain substance.
Advances in understanding of the cell biology of the BBB have opened new avenues and possibilities for improved drug delivery to the CNS. Several carrier or transport systems, enzymes, and receptors that control the penetration of molecules have been identified in the BBB endothelium. Receptor-mediated transcytosis can transport peptides and proteins across the BBB. Methods are available to assess the BBB permeability of drugs at the discovery stage to avoid development of drugs that fail to reach their target site of action in the CNS.
Many of the new developments in the treatment of neurological disorders will be biological therapies and these will require innovative methods for delivery. Cell, gene and antisense therapies are not only innovative treatments for CNS disorders but also involve sophisticated delivery methods. RNA interference (RNAi) as a form of antisense therapy is also described.
The role of drug delivery is depicted in the background of various therapies for neurological diseases including drugs in development and the role of special delivery preparations. Pain is included as it is considered to be a neurological disorder. A special chapter is devoted to drug delivery for brain tumors. Cell and gene therapies will play an important role in the treatment of neurological disorders in the future.
The method of delivery of a drug to the CNS has an impact on the drug's commercial potential. The market for CNS drug delivery technologies is directly linked to the CNS drug market. Values are calculated for the total CNS market and the share of drug delivery technologies. Starting with the market values for the year 2015, projections are made to the years 2020 and 2025. The markets values are tabulated according to therapeutic areas, technologies and geographical areas. Unmet needs for further development in CNS drug delivery technologies are identified according to the important methods of delivery of therapeutic substances to the CNS. Finally suggestions are made for strategies to expand CNS delivery markets. Besides development of new products, these include application of innovative methods of delivery to older drugs to improve their action and extend their patent life.
Profiles of 76 companies involved in drug delivery for CNS disorders are presented along with their technologies, products and 98 collaborations. These include pharmaceutical companies that develop CNS drugs and biotechnology companies that provide technologies for drug delivery. A number of cell and gene therapy companies with products in development for CNS disorders are included. References contains over 420 publications that are cited in the report. The report is supplemented with 53 tables and 13 figures.
Key Topics Covered:
Executive Summary
1. Basics of Drug Delivery to the Central Nervous System
2. Blood Brain Barrier
3. Methods of Drug Delivery to the CNS
4. Delivery of Cell, Gene and Antisense Therapies to the CNS
5. Drug Delivery for Treatment of Neurological Disorders
6. Drug delivery for brain tumors
7. Markets for Drug Delivery in CNS Disorders
8. Companies
9. References
For more information about this report visit http://www.researchandmarkets.com/research/wxxsg2/drug_delivery_in
Source: Jain PharmaBiotech
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Drug Delivery


Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Apple Turns 50: From Garage Startup to AI Crossroads
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 



